Search Back New search Go to resultsDiseaseMain groupHematological Diseases, Non-MalignantProtocol groupLeukocyte diseasesDiseaseHypereosinophilic SyndromeSubgroupICD10D47.5MeSHHypereosinophilic SyndromeSequenceChemotherapyChemo-substanceMepolizumabChemo-substanceMepolizumabChemo-substanceMepolizumabChemo-substanceMepolizumabNo. Substances1 RadiotherapySupportive therapySupportive substanceSupportive substanceSupportive substanceSupportive substanceNo. SubstancesProtocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentiondisease controlRisksDiarrheaHeadacheInfusion ReactionPruritusUpper Respiratory Tract Infection only studiesPublicationAuthorRoufosse FDiseaseFIP1L1-PDGFRA–negative HES oder unkontrolliertes HES, ZweitlinieOriginBrussels, Belgium, HES Mepolizumab study groupProtocols in Revision 1 protocol foundProtocols under revision.Mepolizumab 300, hypereosinophilic syndrome (PID2092 V1.0)
